Plaques from CCL18-treated mice had decreased macrophage content, compatible with a more advanced plaque phenotype (Figure 2F) and tended to have increased collagen content, which is in line with CCL18’s reported pro-fibrotic activity in lung inflammation (18). This evidence concerns the gene CCL18 and inflammatory response.